CAMBRIDGE, United Kingdom, May 28, 2026
AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S. Food and Drug Administration (FDA) approval of Imfinzi® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval introduces the first and only immunotherapy combination regimen available for this patient population and marks the first major therapeutic advancement in this disease setting in more than three decades. Supported by results from the pivotal POTOMAC Phase III trial, the decision provides a new treatment option for patients at high risk of recurrence and disease progression while reinforcing AstraZeneca’s growing leadership in immuno-oncology and bladder cancer innovation.
POTOMAC Phase III Trial Demonstrates Significant Clinical Benefit
The FDA approval was based on data from the global POTOMAC Phase III study, which evaluated Imfinzi in combination with BCG compared with standard BCG therapy alone in patients with BCG-naïve, high-risk NMIBC. Results showed that adding Imfinzi to BCG delivered a 32% reduction in the risk of high-risk disease recurrence, progression, or death compared with BCG treatment alone. The benefit was observed through a disease-free survival hazard ratio of 0.68, demonstrating a statistically significant and clinically meaningful improvement in patient outcomes.
Importantly, the disease-free survival advantage emerged within four months of treatment initiation and remained durable throughout a median follow-up period exceeding five years. Researchers highlighted that the addition of Imfinzi produced sustained disease control without compromising the effectiveness or completion of BCG therapy, a critical consideration for patients receiving curative-intent treatment. These findings position the regimen as a potential new standard of care in high-risk NMIBC.
Addressing a Major Unmet Need in Early Bladder Cancer
Advertisement
Bladder cancer remains one of the most commonly diagnosed cancers globally, with more than 614,000 new cases reported annually. More than 70% of bladder cancer patients are diagnosed with NMIBC, and approximately half of these individuals are considered high risk for recurrence or progression. Despite surgery and BCG therapy remaining the standard treatment approach, recurrence rates can reach 80% within five years, often requiring repeated surgical procedures and, in some cases, complete bladder removal.
The newly approved Imfinzi-based regimen addresses this longstanding challenge by introducing immunotherapy into an earlier stage of disease management. Clinical experts involved in the POTOMAC trial emphasized that reducing recurrence and progression risks can significantly improve long-term outcomes while potentially helping patients avoid more invasive treatments. The approval therefore represents an important advancement for both patients and healthcare providers seeking more effective options in this difficult-to-treat setting.
Expanding AstraZeneca’s Leadership in Bladder Cancer Innovation
The latest approval further strengthens AstraZeneca’s comprehensive bladder cancer portfolio. Imfinzi has already established a presence in muscle-invasive bladder cancer and continues to be evaluated across multiple stages of the disease through several global clinical programs. Recent positive findings from the VOLGA Phase III trial have also highlighted the potential of Imfinzi-based combinations in muscle-invasive bladder cancer patients who are ineligible for cisplatin chemotherapy.
Across its broader oncology strategy, AstraZeneca continues to advance immunotherapy-based approaches designed to improve long-term survival and expand treatment options across numerous cancer types. With more than 414,000 patients treated globally with Imfinzi since its first approval, the therapy has become a cornerstone of the company’s immuno-oncology franchise. The FDA approval in high-risk NMIBC represents another important step toward transforming bladder cancer care and delivering more durable disease control for patients facing one of the most recurrent forms of cancer.
Source: AstraZeneca press release
